Alterity Therapeutics Ltd has released a press release.
Prana provides regulatory update for PBT2
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Prana announces $4.8 million R&D refund
- New Reach2HD data presented at American Neurological Assoc.
- Prana announces $6.5 million R&D refund
- FDA Orphan Drug Designation for PBT2 for Huntington Disease
- Prana to commence Phase 11b trial on PBT2
Later from Alterity Therapeutics
- S&P DJ Indices Announces March Quarterly Rebalance
- S&P DJ Indices Announces March Quarterly Review
- Business Update
- Half Year Accounts
- PBT434 presented at 13th International AD/PD Conference
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics